The Anglo-Swedish pharmaceutical group AstraZeneca announced this Friday encouraging results for a treatment against Covid – 19 which greatly reduces the risk of developing a symptomatic form of the disease in fragile patients.
This antibody treatment, whose code name is AZD 7442, however, had previously not demonstrated its effectiveness on people already exposed to the virus. But by administering it before being in contact with the virus, the results are there, explains AstraZeneca in a press release.
A future medical arsenal? In this case, it reduces by 75% the risk of developing a symptomatic form, according to phase 3 data, that is, large-scale clinical trials designed to measure its safety and efficacy. AstraZeneca even indicates that there have been no severe cases of Covid – or death. These trials, carried out in Spain, France, Belgium, the United Kingdom and the United States, involved 5. 197 participants, including 75% presented with co-morbidities. The treatment was administered intramuscularly.
“With these tremendous results, AZD 7442 could be an important tool in our arsenal to help people who may need more than a vaccine to regain normal lives ”, Myron emphasizes Levin ,, professor at the University of Colorado in the United States and in charge of the trial.
AstraZeneca back in the game “We need other approaches for people who are not well protected by Covid vaccines – 19, ”added Mene Pangalos, senior official at AstraZeneca, who promises to release additional data on the trials later this year. The laboratory specifies that it will submit a file to the health authorities to obtain emergency use or validation under conditions of the treatment, the development of which is funded by the US government.
AstraZeneca was also one of the first to validate its vaccine against Covid – 19, which had however raised questions in due to very rare side effects, which has led countries to limit its use.
Source: www. 20 minutes.fr